Ana Neves Costa

Dr. Ana Neves Costa

orcid

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2011 in Molecular Cell
Verified
Journal Article
Closed access
SRSamuel P. Rowbotham
Samuel P. Rowbotham
LBLeila Barki
Leila Barki
ACAna Neves Costa
Ana Neves Costa
FSFatima Santos
Fatima Santos
WDWendy Dean
Wendy Dean
JMJacqueline E. Mermoud
Jacqueline E. Mermoud

1 November 2013 in Immunity
Verified
Journal Article
Closed access
NFNuno Figueiredo
Nuno Figueiredo
ACAngelo Chora
Angelo Chora
MRMaria Helena Raquel
Maria Helena Raquel
NPNadja Pejanovic
Nadja Pejanovic
PPPedro Pereira
Pedro Pereira
LMLuis Moita
Luis Moita

25 March 2010 in Blood
Verified
Journal Article
Closed access
PDF file
TLTelma Lança
Telma Lança
DCDaniel V. Correia
Daniel V. Correia
CMCatarina Ferreira Moita
Catarina Ferreira Moita
MRMaria Helena Raquel
Maria Helena Raquel
ACAna Neves Costa
Ana Neves Costa
BSBruno Silva-Santos
Bruno Silva-Santos
On the path to successful immunotherapy of hematopoietic tumors, γδ T cells offer great promise because of their human leukocyte antigen (HLA)–unrestricted targeting of a wide variety of leukemias/lymphomas. However, the molecular mechanisms underlying lymphoma recognition by γδ T cells remain unclear. Here we show that the expression levels of UL16-binding protein 1 (ULBP1) determine lymphoma susceptibility to γδ T cell–mediated cytolysis. Consistent with this, blockade of NKG2D, the receptor for ULBP1 expressed on all Vγ9+ T cells, significantly inhibits lymphoma cell killing. Specific loss-of-function studies demonstrate that the role of ULBP1 is nonredundant, highlighting a thus far unique physiologic relevance for tumor recognition by γδ T cells. Importantly, we observed a very wide spectrum of ULBP1 expression levels in primary biopsies obtained from lymphoma and leukemia patients. We suggest this will impact on the responsiveness to γδ T cell–based immunotherapy, and therefore propose ULBP1 to be used as a leukemia/lymphoma biomarker in upcoming clinical trials.

1 October 2012 in Autoimmunity Reviews
Verified
Journal Article
Closed access
RCRita Cascão
Rita Cascão
BVB. Vidal
B. Vidal
MRMaria Helena Raquel
Maria Helena Raquel
ACAna Neves Costa
Ana Neves Costa
NFNuno Figueiredo
Nuno Figueiredo
LMLuis Moita
Luis Moita

1 December 2009 in PLOS ONE
Verified
Journal Article
Open access
PDF file
ACAna Neves Costa
Ana Neves Costa
WWW. Ryan Will
W. Ryan Will
AVAnna T. Vetter
Anna T. Vetter
JMJ. Ross Miller
J. Ross Miller
PVPatrick Varga-Weisz
Patrick Varga-Weisz
Chromatin regulates many key processes in the nucleus by controlling access to the underlying DNA. SNF2-like factors are ATP-driven enzymes that play key roles in the dynamics of chromatin by remodelling nucleosomes and other nucleoprotein complexes. Even simple eukaryotes such as yeast contain members of several subfamilies of SNF2-like factors. The FUN30/ETL1 subfamily of SNF2 remodellers is conserved from yeasts to humans, but is poorly characterized. We show that the deletion of FUN30 leads to sensitivity to the topoisomerase I poison camptothecin and to severe cell cycle progression defects when the Orc5 subunit is mutated. We demonstrate a role of FUN30 in promoting silencing in the heterochromatin-like mating type locus HMR, telomeres and the rDNA repeats. Chromatin immunoprecipitation experiments demonstrate that Fun30 binds at the boundary element of the silent HMR and within the silent HMR. Mapping of nucleosomes in vivo using micrococcal nuclease demonstrates that deletion of FUN30 leads to changes of the chromatin structure at the boundary element. A point mutation in the ATP-binding site abrogates the silencing function of Fun30 as well as its toxicity upon overexpression, indicating that the ATPase activity is essential for these roles of Fun30. We identify by amino acid sequence analysis a putative CUE motif as a feature of FUN30/ETL1 factors and show that this motif assists Fun30 activity. Our work suggests that Fun30 is directly involved in silencing by regulating the chromatin structure within or around silent loci.

29 June 2021 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
ICIrene Cimino
Irene Cimino
HKHanna Kim
Hanna Kim
YTY. C. Loraine Tung
Y. C. Loraine Tung
KPKent Pedersen
Kent Pedersen
DRDebra Rimmington
Debra Rimmington
SOStephen O’rahilly
Stephen O’rahilly
An acute increase in the circulating concentration of glucocorticoid hormones is essential for the survival of severe somatic stresses. Circulating concentrations of GDF15, a hormone that acts in the brain to reduce food intake, are frequently elevated in stressful states. We now report that GDF15 potently activates the hypothalamic–pituitary–adrenal (HPA) axis in mice and rats. A blocking antibody to the GDNF-family receptor α-like receptor completely prevented the corticosterone response to GDF15 administration. In wild-type mice exposed to a range of stressful stimuli, circulating levels of both corticosterone and GDF15 rose acutely. In the case of Escherichia coli or lipopolysaccharide injections, the vigorous proinflammatory cytokine response elicited was sufficient to produce a near-maximal HPA response, regardless of the presence or absence of GDF15. In contrast, the activation of the HPA axis seen in wild-type mice in response to the administration of genotoxic or endoplasmic reticulum toxins, which do not provoke a marked rise in cytokines, was absent in Gdf15−/− mice. In conclusion, consistent with its proposed role as a sentinel hormone, endogenous GDF15 is required for the activation of the protective HPA response to toxins that do not induce a substantial cytokine response. In the context of efforts to develop GDF15 as an antiobesity therapeutic, these findings identify a biomarker of target engagement and a previously unrecognized pharmacodynamic effect, which will require monitoring in human studies. Significance GDF15, a hormone produced by a wide variety of cells undergoing different types of stress, acts on a receptor in the brain where it transmits signals that are perceived by the organism as aversive. We now report an action of GDF15, whereby it activates the endocrine stress response and increases circulating levels of the principal glucocorticoid (a “stress” steroid). By studying mice genetically deficient in GDF15, we also demonstrate that GDF15 is a key signal through which damage due to toxic chemicals activates the steroid stress response. GDF15 is currently being explored as an antiobesity drug and examination of the degree and duration of the steroid effect will need to be incorporated into any human trials.